Table 1.

Clinical response to ICI treatment in MSS colorectal cancers with POLE mutations.

Ref.	Age	Sex	Race	MMR status	Prior to ICI treatment	POLE	TMB/Mb	ICI treatment	Response (months)
(15)	34	M	Asian	MSS	adjuvant chemo	p.P286R	--	pembrolizumab	stable disease (>7)
(16)	81	M	Hispanic	KRAS-MSS	adjuvant chemo	p.V411L	122	pembrolizumab	partial response (>12)
(17)	44	M	--	KRAS-MSS	neoadjuvant radiation	p.V411L	200	pembrolizumab	complete response (> 28)
(18)	29	M	Asian	MSS	adjuvant chemo	p.F367S	103	pembrolizumab	complete response (>49)